Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2013
At a glance
- Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 12 Jun 2012 Actual patient number 401 added as reported by ClinicalTrials.gov.
- 12 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2012 Additional lead trial centre (Almedis) added as reported by ClinicalTrials.gov.